DelMar Pharmaceuticals Inc. (DMPI): Check on its recent ratings


DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) changes shares on Tuesday trading session, with a change of -13.63% or -$0.12 shares. The trading starts at $0.80 and closed at $0.91 throughout the day. The trading session low price was $0.7177 and day high was $0.83 on Tuesday, June 23. After the session, the Healthcare sector daily volume shifted to 1.9 million while its average volume is 565.77K. In other hand, the DMPI market cap reached to $9.13M. While, its current target price is $0.79 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -31.95% and down -14.20% for month. Its quarterly performance was 85.87% above, while its half year performance is up 48.05%. DMPI yearly performance stood at negative -49.40% and rise 14.46% for year-to-date. Current recommendation for DelMar Pharmaceuticals Inc. is 2.00.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. DMPI EPS (TTM) for 12-month is -1.41. EPS for this year is 41.80%, while for the next year its value is -0.46. Its EPS Q/Q reached 74.40%. It has an EPS of -22.90% down for past five years.

Let’s take a look on the analyst recommendations on DMPI for the current month and previous month. For the current month, 2 of 2 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $2.00-$4.00. Average target price for DMPI was reached at $3.00.

The insider ownership moved to 0.10% and institutional holding shifted to 1.90%.

The company posted an EPS (TTM) of -1.41. According to the most recent quarter report on (Jun 2020), 2 analysts estimated an average EPS of -0.12, while -1 EPS posted a year ago period. Analyst Estimated EPS for DMPI published in the report was -0.17–0.07 during the same period. Comparing with last year, the average estimated EPS was -1 which is lower than -0.17 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for DMPI rise 26.76% for period of 200 days. SMA for 50 days was 2.18% which is showing green signal, while SMA-20 was -22.47%. The moving average value for DelMar Pharmaceuticals Inc. (DMPI) is 0.6229 and 0.8722 for 200 and 50 days respectively.